Jerome Guitton
Overview
Explore the profile of Jerome Guitton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
118
Citations
949
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Dufraigne A, Perinel-Ragey S, Guitton J, Cohen S, Thiery G, Launay M
Ther Drug Monit
. 2024 Mar;
46(4):553-555.
PMID: 38531815
No abstract available.
12.
Febvey-Combes O, Guitton J, Marec-Berard P, Faure-Conter C, Blanc E, Chabaud S, et al.
BMC Pediatr
. 2024 Mar;
24(1):196.
PMID: 38504218
Background: Ifosfamide is a major anti-cancer drug in children with well-known renal toxicity. Understanding the mechanisms underlying this toxicity could help identify children at increased risk of toxicity. Methods: The...
13.
Zala M, Lipinski B, Costechareyre C, Jarrosson L, Teinturier R, Julia E, et al.
Leukemia
. 2024 Jan;
38(2):430-434.
PMID: 38225454
No abstract available.
14.
Ziegler D, Czarnecka-Herok J, Vernier M, Scholtes C, Camprubi C, Huna A, et al.
NPJ Aging
. 2024 Jan;
10(1):5.
PMID: 38216569
Cellular senescence is a cell program induced by various stresses that leads to a stable proliferation arrest and to a senescence-associated secretory phenotype. Accumulation of senescent cells during age-related diseases...
15.
Philippe M, Guitton J, Goutelle S, Thoma Y, Favier B, Chtiba N, et al.
Ther Drug Monit
. 2023 Nov;
46(1):127-131.
PMID: 37941111
Background: Venetoclax (VNX)-based regimens have demonstrated significantly favorable outcomes in patients with acute myeloid leukemia (AML) and are now becoming the standard treatment. Tyrosine kinase inhibitors are administered at a...
16.
Kaduk K, Henry T, Guitton J, Meunier M, Thura D, Hadj-Bouziane F
Neuropharmacology
. 2023 Sep;
241:109736.
PMID: 37774942
Our ability to engage and perform daily activities relies on balancing the associated benefits and costs. Rewards, as benefits, act as powerful motivators that help us stay focused for longer...
17.
Beguin J, Laloy E, Cochin S, Gantzer M, Farine I, Pichon C, et al.
Mol Ther Oncolytics
. 2023 Aug;
30:103-116.
PMID: 37635744
TG6002 is an oncolytic vaccinia virus expressing FCU1 protein, which converts 5-fluorocytosine into 5-fluorouracil. The study objectives were to assess tolerance, viral replication, 5-fluorouracil synthesis, and tumor microenvironment modifications to...
18.
Flament E, Gaulier J, Paret N, Jarrier N, Bruneau C, Creusat G, et al.
Drug Test Anal
. 2023 Jul;
16(4):331-338.
PMID: 37488986
Despite prevention efforts, many cases of mushroom poisoning are reported around the world every year. Among the different toxins implicated in these poisonings, muscarine may induce parasympathetic neurological damage. Muscarine...
19.
Piecyk M, Triki M, Laval P, Duret C, Fauvre J, Cussonneau L, et al.
Mol Oncol
. 2023 Jul;
18(9):2111-2135.
PMID: 37452637
Nutrient availability is a key determinant of tumor cell behavior. While nutrient-rich conditions favor proliferation and tumor growth, scarcity, and particularly glutamine starvation, promotes cell dedifferentiation and chemoresistance. Here, linking...
20.
Puszkiel A, You B, Payen L, Lopez J, Guitton J, Rousset P, et al.
Cancer Chemother Pharmacol
. 2023 Apr;
91(5):413-425.
PMID: 37010549
Purpose: The objective was to develop a pharmacokinetic-pharmacodynamic (PK-PD) model linking everolimus and sorafenib exposure with biomarker dynamics and progression-free survival (PFS) based on data from EVESOR trial in patients...